Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HM11260C in Adult Obesity Patients Without Diabetes Mellitus
NCT06174779Phase 3Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Jan 2024
- Primary completion
- Aug 2025
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of efpeglenatide in obesity, sponsored by Hanmi Pharmaceutical. Started Jan 2024; status: completed.
02
Drugs
efpeglenatide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06174779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06174779.